UK shareholder meetings calendar - next 7 days
22nd May 2025 14:05
Hemogenyx Pharmaceuticals PLC - London-headquartered biopharmaceutical company focused on treatments for blood diseases - Says it has filed, with the US Food & Drug Administration, an amendment to the clinical protocol for its ongoing phase 1 clinical trial of HG-CT-1 to include paediatric patients with relapsed/refractory acute myeloid leukemia, or R/R AML. CAR-T therapy HG-CT-1 is currently undergoing clinical trials to treat R/R AML in adults. Company says the amendment "seeks to expand eligibility for the trial beyond adult patients to include children and adolescents with R/R AML, an aggressive disease with limited treatment options and poor prognosis in the relapsed/refractory setting". Adds that expanding eligibility reflects its commitment to broadening the potential impact of HG-CT-1, and to addressing a critical unmet medical need in paediatric oncology. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
Hemogenyx Pharmaceuticals PLC - London-based biotechnology company - Administers its first in-human dose of HG-CT-1, the firm's proprietary CAR-T cell therapy, used in the treatment of relapsed or refractory acute myeloid leukemia in adults. Says further updates on the clinical trial will be provided "in due course". Read More
Hemogenyx Pharmaceuticals PLC - London-based biotechnology company - Says it has raised GBP340,000 through the placing of 100,000 shares at 340p each. The financing will be dedicated to the clinical trial of its HG-CT-1 drug, which is used for treatment of acute myeloid leukaemia in adults. The first patient for the trial has been recruited and is being tested to ensure they satisfy the clinic protocol. Read More
(Alliance News) - Hemogenyx Pharmaceuticals PLC on Monday reported the opening of the first clinical site in its HG-CT-1 phase 1 trial. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
Hemogenyx Pharmaceuticals PLC - London-based biopharmaceutical company focused on treatments for blood diseases - Schedules the opening of the first clinical site for the phase 1 clinical trial of Hemo-Car-T, a treatment for relapsed or refractory acute myeloid leukemia in adults, formally called HG-CT-1, for the third week of November. The site will open following clearance from the Institutional Review Board and a site initiation visit. Read More
(Alliance News) - Hemogenyx Pharmaceuticals PLC on Friday said its pretax loss narrowed in the first half of 2024, following a reduction in expenses. Read More
(Alliance News) - The following is a round-up of earnings for London-listed companies, issued on Friday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
Hemogenyx Pharmaceuticals PLC - biopharmaceutical company focused on treatments for blood diseases - Updates on its ongoing activities and progress. Says an additional US medical centre has been added to its list of clinical trial sites for Hemo-Car T. This will enhance the scope and expedite the timeline for the implementation of clinical trials. Hemogenyx says it is looking to expand Hemo-Car T to include pediatric acute myeloid leukemia and a subset of pediatric acute lymphoblastic leukemia patients. An amendment to the clinical protocol is currently under review by third party experts. If approved, the company will seek to implement the clinical trials for pediatric AML. Further, company says it is advancing studies for CDX, a bispecific antibody designed for treating relapsed and/or refractory AML, a subset of ALL, and for conditioning in bone marrow transplants. Read More
(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Hemogenyx Pharmaceuticals PLC on Thursday said it has raised GBP3.3 million through a placing. Read More
(Alliance News) - Hemogenyx Pharmaceuticals PLC on Friday said research has shown that its proprietary chimeric bait receptor can be delivered into the brain through programmed microglial cells and could be used for the treatment of brain cancers and some neurodegenerative diseases. Read More
(Alliance News) - Hemogenyx Pharmaceuticals PLC on Wednesday said its chimeric bait receptor can be delivered intranasally in the form of messenger RNA for the "potential" treatment of airborne viral infections. Read More
Hemogenyx Pharmaceuticals PLC - London-based biopharmaceutical company focused on treatments for deadly blood diseases - US Food & Drug Administration has lifted clinical hold on company's investigational new drug application for Hemo-Car-T to treat acute myeloid leukemia. FDA placed therapy on clinical hold in July due to a splicing deficiency during manufacture of the lentivirus used to produce Car-T cells. Hemogenyx in August produced a "detailed plan, supported by laboratory tests" to address FDA's concerns, which was accepted the following month. Read More